www.fdanews.com/articles/204493-tivdak-wins-accelerated-approval-for-cervical-cancer
![Seagen-Genmab Logos](https://www.fdanews.com/ext/resources/test/Drug-Images4/Seagen-Genmab-Logos.png?t=1632270287&width=430)
Tivdak Wins Accelerated Approval for Cervical Cancer
September 22, 2021
The FDA has granted accelerated approval to Seagen’s and Genmab’s antibody-drug conjugate Tivdak (tisotumab vedotin-tftv) for treating women with recurrent or metastatic cervical cancer whose disease has progressed during or following chemotherapy.
The approval was supported by a 101-person phase 2 trial where 24 percent of patients taking Tivdak had a positive response to treatment, with the median duration of response lasting 8.3 months.
The FDA said Tivdak must carry a boxed warning for ocular toxicity, as well as warnings for peripheral neuropathy, hemorrhage, pneumonitis and embryo-fetal toxicity.
Under the accelerated approval pathway, the companies must conduct a confirmatory trial to maintain approval.